CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis.
Cutaneous leishmaniasis (CL) affects the lives of 0.7-1 million people every year causing lesions that take months to heal. These lesions can result in disfiguring scars with psychological, social and economic consequences. Antimonials are the first line of therapy for CL, however the treatment is l...
Main Authors: | Seth G Thacker, Ian L McWilliams, Beatrice Bonnet, Lydia Halie, Serge Beaucage, Swaksha Rachuri, Ranadhir Dey, Robert Duncan, Farrokh Modabber, Stephen Robinson, Graeme Bilbe, Byron Arana, Daniela Verthelyi |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-02-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | https://doi.org/10.1371/journal.pntd.0008050 |
Similar Items
-
Pentavalent antimonials: old drugs for new diseases
by: Philip Davis Marsden
Published: (1985-09-01) -
Pentavalent antimonials: old drugs for new diseases
by: Philip Davis Marsden
Published: (1985-09-01) -
Pentavalent Antimonials: New Perspectives for Old Drugs
by: Raul R. Ribeiro, et al.
Published: (2009-06-01) -
Mixed Antimony(V) Complexes with Different Sugars to Modulate the Oral Bioavailability of Pentavalent Antimonial Drugs
by: Weverson A. Ferreira, et al.
Published: (2014-04-01) -
Synergistic Radiosensitization Effect of Combination of CpG ODNs and Herceptin
by: Chieh-Han Yang, et al.
Published: (2006)